32 results on '"Bibby AC"'
Search Results
2. PET-CT-guided versus CT-guided biopsy in suspected malignant pleural thickening: a randomised trial.
- Author
-
de Fonseka D, Arnold DT, Smartt HJM, Culliford L, Stadon L, Tucker E, Morley A, Zahan-Evans N, Bibby AC, Lynch G, Mishra E, Khan S, Haris M, Steer H, Lewis L, Ionescu A, Harvey J, Blyth K, Rahman NM, Edey AE, Rogers CA, and Maskell NA
- Subjects
- Humans, Positron Emission Tomography Computed Tomography, Tomography, X-Ray Computed, Image-Guided Biopsy methods, Biopsy, Pleural Diseases, Pleural Neoplasms diagnostic imaging, Pleural Neoplasms pathology
- Abstract
Background: Pleural biopsy is the gold standard for diagnosis of pleural malignancy but a significant proportion will have an inconclusive biopsy despite ongoing clinical suspicion of malignancy. We investigated whether positron emission tomography-computed tomography (PET-CT) targeted pleural biopsy is superior to standard CT-guided pleural biopsy following an initial non-diagnostic biopsy., Methods: The TARGET trial was a multicentre, parallel group randomised trial. Patients with a previous inconclusive pleural biopsy but an ongoing suspicion of pleural malignancy were randomised (1:1) to receive either CT-guided biopsy (standard care) or PET-CT followed by a targeted CT biopsy (intervention). The primary outcome was pleural malignancy correctly identified from the trial biopsy., Results: Between September 2015 and September 2018, 59 participants were randomised from eight UK hospital sites: 29 to CT-only followed by targeted biopsy and 30 to PET-CT followed by targeted biopsy. The proportion of pleural malignancy correctly identified was similar between the groups (risk ratio 1.03 (95% CI 0.83-1.29); p=0.77). The sensitivity of the trial biopsy to identify pleural malignancy was 79% (95% CI 54-94%) in the CT-only group versus 81% (95% CI 54-96%) in the PET-CT group., Conclusions: The results do not support the practice of PET-CT to guide pleural biopsies in patients with a previous non-diagnostic biopsy. The diagnostic sensitivity in the CT-only group was higher than anticipated and supports the practice of repeating a CT-guided biopsy following an inconclusive result if clinical suspicion of malignancy persists., Competing Interests: Conflict of interest: None declared., (Copyright ©The authors 2024.)
- Published
- 2024
- Full Text
- View/download PDF
3. Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort.
- Author
-
Conway RJH, Smith N, Cooper W, Lynch G, Patole S, Symonds J, Edey A, Maskell NA, and Bibby AC
- Abstract
Objective: Mesothelioma varies in clinical phenotype and survival. Clinical trials are unavoidably affected by selection bias, reducing generalisability. ASSESS-meso is a UK, multicentre, prospective, mesothelioma cohort study (ISRCTN61861764). This pre-specified interim analysis, conducted when recruitment reached 25% of target, summarised participant characteristics and evaluated external validity through comparison with real-world and clinical trial cohorts., Methods: The study took place at 14 hospitals across the UK. People diagnosed with mesothelioma, at any anatomical site, were eligible. Clinical, radiological and biochemical data were collected at enrolment. In this interim report, the external validity of the cohort was investigated through comparison of baseline demographic data with populations included in the 2020 UK National Mesothelioma Audit (real-world cohort), and CHECKMATE-743 and MAPS trials (clinical trial cohorts)., Results: 244 patients were enrolled between 7 April 2017 and 1 March 2022. The cohort was predominantly male (195 out of 244; 80%) with a median age of 74 years. Pleural disease and epithelioid subtypes were most prevalent. ASSESS-meso participants were more similar to the real-world population with regard to age, performance status, disease site and stage than the clinical trial population. ASSESS-meso participants were more likely to be formally staged and less likely to have undifferentiated histology compared with the real-world cohort, possibly reflecting high rates of discussion of ASSESS-meso participants at regional mesothelioma multidisciplinary team meetings. As expected, poorer performance status, non-epithelioid histology and neutrophil-lymphocyte ratio were associated with shorter survival in the adjusted analysis., Conclusion: ASSESS-meso is representative of the UK mesothelioma population. Future outputs from the cohort will help characterise different mesothelioma phenotypes with high external validity., Competing Interests: Conflict of interest: A.C. Bibby has received an unrestricted research grant from Fujirebio and the Avon Mesothelioma Foundation. Conflict of interest: N.A. Maskell has received grants from Becton Dickinson and Rocket Medical, and is a member of the advisory board for Becton Dickinson. Conflict of interest: The remaining authors declare no conflicts of interests., (Copyright ©The authors 2023.)
- Published
- 2023
- Full Text
- View/download PDF
4. British Thoracic Society Guideline for pleural disease.
- Author
-
Roberts ME, Rahman NM, Maskell NA, Bibby AC, Blyth KG, Corcoran JP, Edey A, Evison M, de Fonseka D, Hallifax R, Harden S, Lawrie I, Lim E, McCracken D, Mercer R, Mishra EK, Nicholson AG, Noorzad F, Opstad KS, Parsonage M, Stanton AE, and Walker S
- Subjects
- Humans, Pleural Diseases diagnosis, Pleural Diseases therapy, Pleural Effusion therapy
- Abstract
Competing Interests: Competing interests: None declared. BTS Declarations of Interest forms have been completed by all members for each year they were part of the GDG. Details of these forms can be obtained from BTS Head Office. 'Declarations of Interests' was a standing item at each GDG meeting.
- Published
- 2023
- Full Text
- View/download PDF
5. Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso).
- Author
-
Conway RJH, Symonds J, Walton D, Probets J, Comins C, Stadon L, Harvey JE, Blyth KG, Maskell NA, and Bibby AC
- Subjects
- Humans, Prospective Studies, Biomarkers, Demography, Observational Studies as Topic, Lung Neoplasms, Mesothelioma diagnosis, Mesothelioma, Malignant
- Abstract
Introduction: Mesothelioma is a heterogeneous disease that can be challenging to monitor and prognosticate. ASSESS-meso is a multicentre, prospective, longitudinal observational cohort study of patients with mesothelioma. The primary aim is to describe different clinical phenotypes and investigate predictive and prognostic factors, including biomarkers from blood and pleural fluid. The secondary aim is to provide a resource for future trials and substudies., Methods and Analysis: We aim to recruit 700 patients with a histological, cytological or clinicopathological diagnosis of mesothelioma, at any anatomical site (pleural, peritoneal, pericardial, etc). Longitudinal data will be collected, including clinical information, radiological investigations, blood tests and patient-reported outcome measures for breathlessness, chest pain and sweats. Preplanned analyses will use Cox proportional hazards method to evaluate factors associated with survival, linear and logistic regression models to investigate associations with symptoms, and analysis of variance modelling to explore changes in symptoms over time., Ethics and Dissemination: Ethical approval has been granted by the Research Ethics Committee South West-Central Bristol (17-SW-0019) and Health Research Authority (IRAS ID 220360). A study steering committee has been established and results will be published OpenAccess in peer-reviewed journals., Trial Registration Number: ISRCTN: 61861764., Competing Interests: Competing interests: ACB has received grants from Fujirebio. JEH is a trustee of the Avon Mesothelioma Foundation. KGB has received grants from Rocket Medical. NAM has received grants from Becton Dickinson & Rocket Medical and is a member of the advisory board for Becton Dickinson. No members of the project team received any financial incentives for their contribution., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
6. A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology.
- Author
-
Bibby AC, Zahan-Evans N, Keenan E, Comins C, Harvey JE, Day H, Rahman NM, Fallon JE, Gooberman-Hill R, and Maskell NA
- Abstract
Background: Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy with a poor prognosis. Systemic immunotherapy is an effective frontline treatment for MPM, and there is a scientific rationale supporting the possible efficacy of local, i.e. intra-pleural immune modulators. Trial of intra-pleural bacterial immunotherapy (TILT) investigated the feasibility of performing a randomised trial of intra-pleural bacterial immunotherapy in people with MPM, using the trials within cohorts (TwiC) methodology., Methods: TILT was a multicentre, three-armed, randomised, feasibility TwiC of intra-pleural OK432, BCG, or usual care in people with MPM. Eligible participants were identified from within the ASSESS-meso study, a prospective, longitudinal, observational cohort study, and were randomly selected to be offered a single dose of OK432 or BCG, via an indwelling pleural catheter. The primary outcome was feasibility, evaluated against prespecified recruitment, attrition and data completeness targets. The acceptability of trial processes and interventions was assessed during qualitative interviews with participants and family members at the end of the trial. TILT was registered prospectively on the European Clinical Trials Registry (EudraCT number 2016-004,727-23) and the ISRCTN Register on 04 December 2017., Results: Seven participants were randomised from a planned sample size of 12; thus, the 66% recruitment rate target was not met. Two participants withdrew after randomisation, breaching the pre-stated attrition threshold of 10%. It was not possible to maintain blinding of control participants, which negated a fundamental tenet of the TwiC design. The trial processes and methodology were generally acceptable to participants and relatives, despite several recipients of intra-pleural bacterial agents experiencing significant local and systemic inflammatory responses., Conclusion: It was possible to design a clinical trial of an investigational medicinal product based on the TwiC design and to obtain the necessary regulatory approvals. However, whilst acceptable to participants and relatives, the TwiC design was not a feasible method of investigating intra-pleural bacterial immunotherapy in people with MPM. Future trials investigating this topic should consider the eligibility constraints and recruitment difficulties encountered., Trial Registration: TILT was registered prospectively on the European Clinical Trials Registry (EudraCT number 2016-004727-23 ) and the ISRCTN Register ( 10432197 ) on 04 December 2017., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
7. Lymphocyte predominance in blood, pleural fluid, and tumour stroma; a prognostic marker in pleural mesothelioma.
- Author
-
De Fonseka D, Arnold DT, Morley AJ, Brett M, Bhatt N, Edey A, Daly R, Bibby AC, and Maskell NA
- Subjects
- Humans, Lymphocytes metabolism, Prognosis, Mesothelioma diagnosis, Mesothelioma, Malignant, Pleural Neoplasms diagnosis
- Abstract
Background: As promising novel treatments develop for malignant pleural mesothelioma (MPM), early prognostication has become increasingly important. Circulating and local inflammatory cells are known to play a significant role in other tumour types. We assessed the proportion of lymphocyte populations within blood, pleural fluid and tumour stroma to prognosticate patients with MPM at diagnosis., Methods: Consecutive patients diagnosed with biopsy-proven MPM were prospectively recruited to an observational cohort study and followed up for a minimum of 7.5 years. Blood and pleural fluid results at presentation were extracted from the medical records. Biopsy specimens were independently reviewed by 2 pathologists who scored the degree of lymphocytic and neutrophilic infiltration., Results: Baseline results were available for 184 patients. The predominant pleural fluid cell type was calculable for 84 patients and 118 patients had biopsy specimens available for review. A low blood neutrophil/lymphocyte ratio (NLR < 4) inferred a better prognosis with a median survival of 420 days versus 301 days (p < 0.01). Survival was better for patients with a lymphocyte-predominant pleural effusion (430 vs 306 days, p < 0.01). Lymphocyte infiltration of tumour stroma was also associated with improved survival (n = 92, survival 430 days) compared with neutrophilic or acellular samples (n = 26, survival 342 days p < 0.01). In multivariable modelling lymphocyte predominance in blood, pleural fluid and tumour stroma were all associated with a better prognosis., Conclusions: Lymphocyte predominance within tumour stroma, pleural fluid or blood infers a better prognosis in patients with MPM., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
8. The priorities of people with mesothelioma and their carers: A qualitative interview study of trial participation and treatment decisions.
- Author
-
Bibby AC, Morley AJ, Keenan E, Maskell NA, and Gooberman-Hill R
- Subjects
- Communication, Decision Making, Humans, Qualitative Research, Quality of Life, Caregivers, Mesothelioma therapy
- Abstract
Purpose: Treatment options for mesothelioma are increasing, as are the number of clinical trials available to patients. However, little is known about patients' and relatives' priorities when making decisions about treatment and trial participation. The aim of this study was to provide insight into people's experiences of participating in clinical research and explore the factors influencing decision-making., Methods: Face to face, semi-structured interviews were undertaken with mesothelioma patients who were participating in the TILT trial (a randomised trial of intra-pleural immunotherapy) and their relatives. Interviews were audio-recorded, transcribed and analysed thematically., Results: Twelve people were interviewed, comprising five mesothelioma patients and seven relatives. Four themes were identified relating to the experience of mesothelioma: physicality, quality of life, uncertainty and risk, and planning for an unpredictable future. A further theme related to attitudes to research participation., Participants: valued physical strength and were careful not to jeopardise this with potential side effects of medication. Quality of life was important and was often prioritised over survival. Participants found ambiguity challenging and sought certainty, potentially in response to the uncertainty surrounding their future. The desire for certainty impacted on risk perception; an important factor in decision-making. Relatives often advocated on behalf of patients and were more reluctant about research participation due to concern about potential risks., Conclusion: The study confirmed previous qualitative findings around physicality, stoicism and uncertainty, building on these themes to highlight their influence on decision-making. Important findings for practice include the challenges associated with risk communication and the differing care needs and attitudes to research of relatives., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
9. Is Systemic Anticancer Therapy Associated With Higher Rates of Malignant Pleural Effusion Control in People With Pharmacologically Sensitive Tumors?: A Retrospective Analysis of Prospectively Collected Data.
- Author
-
Holling N, Patole S, Medford ARL, Maskell NA, and Bibby AC
- Subjects
- Aged, Antineoplastic Agents, Immunological pharmacology, Catheters, Indwelling statistics & numerical data, Correlation of Data, Early Medical Intervention methods, Female, Humans, Immune Checkpoint Inhibitors pharmacology, Immunotherapy methods, Male, Retrospective Studies, United Kingdom epidemiology, Molecular Targeted Therapy methods, Neoplasms classification, Neoplasms complications, Neoplasms genetics, Neoplasms therapy, Neoplasms, Hormone-Dependent complications, Neoplasms, Hormone-Dependent therapy, Pleural Effusion, Malignant diagnostic imaging, Pleural Effusion, Malignant epidemiology, Pleural Effusion, Malignant etiology, Pleural Effusion, Malignant therapy, Pleurodesis methods, Pleurodesis statistics & numerical data
- Abstract
Background: Malignant pleural effusions (MPEs) often cause symptoms, and guidelines recommend early definitive intervention. However, observational data suggest that systemic anticancer treatment (SACT) may control MPE caused by certain pharmacologically sensitive tumors., Research Question: Is SACT associated with higher rates of MPE resolution in people with pharmacologically sensitive tumors?, Study Design and Methods: This was a retrospective analysis of prospectively collected data from an observational cohort study of people diagnosed with MPE from lung, breast, ovarian, and hematologic malignancy between May 11, 2008, and August 6, 2017. MPE resolution (defined as radiologic resolution with removal of drain or catheter and cessation of interventions) was compared in pharmacologically sensitive (high-grade lymphoma, small cell or target-mutation-positive lung cancer, and hormone-receptor-positive breast or ovarian cancer) and nonsensitive (remainder of cohort) tumors, with and without SACT. Secondary outcomes included time to resolution, 3-month resolution rates, and total pleural interventions., Results: Of 280 patients, 127 had sensitive and 153 had nonsensitive tumors. One hundred seventy-one received SACT, and 109 did not. More patients with sensitive tumors achieved MPE resolution than those with nonsensitive tumors (53/127 [41.7%] vs 42/153 [27.5%]; P = .01), and this occurred predominantly after receipt of SACT. However, hematologic malignancies were overrepresented in the sensitive group, with high rates of SACT use and MPE resolution. After adjustment for this and other confounders, no relationship was found among pharmacologic sensitivity, SACT, and MPE resolution (adjusted OR, 1.4; 95% CI, 0.5-4.1). The strongest predictor of MPE resolution was administration of chemical pleurodesis (adjusted OR, 6.2; 95% CI, 3.3-11.7). In sensitive tumors, MPE resolution occurred without chemical pleurodesis in 14 of 52 patients (26.9%; 95% CI, 15.6%-41.1%) after SACT and in 5 of 22 patients (22.7%; 95% CI, 8.2%-47.2%) without SACT., Interpretation: In this observational study, SACT was not associated independently on MPE resolution in pharmacologically sensitive tumors. Randomized trials are required, but with current data, patients with symptomatic MPE should receive early definitive pleural intervention regardless of underlying tumor or intended treatment., (Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
10. Standards of care in mesothelioma treatment.
- Author
-
Harden SV, Darlison L, Beckett P, and Bibby AC
- Subjects
- Humans, United Kingdom, Medical Oncology standards, Mesothelioma therapy, Standard of Care
- Abstract
The UK has the highest incidence of mesothelioma in the world, but services vary across the country partly due to uneven geographical distribution of cases. The Mesothelioma UK-funded national organisational audit has highlighted challenges in accessing diagnostic procedures such as thoracoscopy, as well as identifying examples of best practice, including access to clinical trials and specialist therapeutic procedures. To ensure equitable and optimal patient care, cancer alliances should have established referral pathways to specialist multidisciplinary team (MDT) services for discussion of all mesothelioma patients.
- Published
- 2020
- Full Text
- View/download PDF
11. The Prevalence and Clinical Relevance of Nonexpandable Lung in Malignant Pleural Mesothelioma. A Prospective, Single-Center Cohort Study of 229 Patients.
- Author
-
Bibby AC, Halford P, De Fonseka D, Morley AJ, Smith S, and Maskell NA
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms therapy, Male, Mesothelioma therapy, Mesothelioma, Malignant, Middle Aged, Pleural Effusion, Malignant therapy, Prevalence, Prospective Studies, Survival Analysis, United Kingdom, Lung physiopathology, Lung Neoplasms mortality, Lung Neoplasms pathology, Mesothelioma mortality, Mesothelioma pathology, Pleural Effusion, Malignant etiology
- Abstract
Rationale: Nonexpandable lung is a recognized phenomenon that can create management challenges in patients with mesothelioma. Its prevalence and clinical importance are unknown. Objectives: The aim of this study was to describe the prevalence of nonexpandable lung and to evaluate whether there was any association between nonexpandable lung and survival in a clinical cohort of patients with mesothelioma. Methods: This was a prospective, observational cohort study of patients with mesothelioma who were seen in a single center between March 1, 2008, and August 3, 2017. Baseline characteristics were collected at diagnosis. Serial chest radiographs were assessed for the presence of pleural effusions and nonexpandable lung (defined as a lack of lung expansion after pleural aspiration or drainage). Patients were followed until they died or were censored on March 14, 2019. Results: Of 229 patients, 192 (82.7%) had a pleural effusion at presentation, and nonexpandable lung was observed in 64 of these 192 patients (33.3%). Breathlessness and cough were more frequent in patients with pleural effusions, especially in those with underlying nonexpandable lung, whereas chest pain was more prevalent in patients without effusions. Patients with pleural effusions, both with and without underlying nonexpandable lung, were more likely to have epithelioid or early-stage disease and to receive chemotherapy than patients with no pleural effusion. Nonexpandable lung was an independent risk factor for short survival, with a hazard ratio for mortality of 1.80 (95% confidence interval, 1.16-2.80) compared with patients without nonexpandable lung. The presence of a pleural effusion did not appear to be associated with a worse prognosis compared with patients with an effusion (adjusted hazard ratio, 1.86; 95% confidence interval, 0.93-3.72). Conclusions: This is the first study to describe the prevalence and clinical implications of nonexpandable lung in mesothelioma. It demonstrates that nonexpandable lung is a relatively common phenomenon that is associated with significant symptomatology and shorter survival. Keywords: mesothelioma; nonexpandable lung; pleural effusion.
- Published
- 2019
- Full Text
- View/download PDF
12. Is pleural infection associated with longer survival in mesothelioma? A population-based cohort study using data from Hospital Episode Statistics.
- Author
-
Bibby AC, de Fonseka D, Carslake DJ, and Maskell NA
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, England epidemiology, Female, Humans, Male, Mesothelioma complications, Middle Aged, Pleural Neoplasms complications, Proportional Hazards Models, Infections complications, Mesothelioma mortality, Pleura, Pleural Neoplasms mortality
- Abstract
Background: Historically pleural infection was thought to be associated with longer survival in thoracic malignancies. The aim of this population-based cohort study was to investigate this hypothesis in mesothelioma, using national data from a high incidence country., Methods: Case records for all patients with mesothelioma seen in English hospitals between 01/01/2005 and 31/12/2014 were extracted from Hospital Episode Statistics using International Classification of Diseases Tenth Edition (ICD-10) codes. Episodes of pleural infection were identified. Linked mortality data was obtained from the Office of National Statistics. The primary outcome was all-cause mortality. The explanatory variable was pleural infection. Cox proportional hazards model was used to analyse survival, with pleural infection, chemotherapy and thoracic surgery handled as time-variable co-factors., Results: Of 22,215 patients with mesothelioma, 512 (2.3%) developed pleural infection at some point in their illness. Overall median survival was 7.0 months (IQR 2.3-16.4). Pleural infection was associated with shorter survival in the immediate post-infection period (up to 30 days - HR 1.81, 95% CI 1.45-2.22) and longer term (>30 days - HR 1.81, 95% CI 1.63-1.99). Other factors associated with increased mortality were age, male gender and being diagnosed as an inpatient. Receiving chemotherapy and being less economically deprived were associated with longer survival., Conclusion: Pleural infection occurred in 2.3% of people with mesothelioma and was associated with shorter survival. This refutes previous reports suggesting pleural infection may be associated with better outcomes in thoracic malignancy., (Copyright © 2019. Published by Elsevier Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
13. ERS/EACTS statement on the management of malignant pleural effusions.
- Author
-
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Maskell NA, and Cardillo G
- Subjects
- Europe, Humans, Consensus, Disease Management, Pleural Effusion, Malignant therapy, Pleurodesis standards, Societies, Medical, Thoracic Surgery, Thoracic Surgical Procedures standards
- Abstract
Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomized clinical trials have been published that have changed the landscape of MPE management. The European Respiratory Society (ERS) and the European Association for Cardio-Thoracic Surgery (EACTS) established a multidisciplinary collaboration of clinicians with expertise in the management of MPE with the aim of producing a comprehensive review of the scientific literature. Six areas of interest were identified, including the optimum management of symptomatic MPE, management of trapped lung in MPE, management of loculated MPE, prognostic factors in MPE, whether there is a role for oncological therapies prior to intervention for MPE and whether a histological diagnosis is always required in MPE. The literature revealed that talc pleurodesis and indwelling pleural catheters effectively manage the symptoms of MPE. There was limited evidence regarding the management of trapped lung or loculated MPE. The LENT score was identified as a validated tool for predicting survival in MPE, with Brims' prognostic score demonstrating utility in mesothelioma prognostication. There was no evidence to support the use of oncological therapies as an alternative to MPE drainage, and the literature supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning.Management options for malignant pleural effusions have advanced over the past decade, with high-quality randomized trial evidence informing practice in many areas. However, uncertainties remain and further research is required http://ow.ly/rNt730jOxOS.
- Published
- 2019
- Full Text
- View/download PDF
14. Recurrence rates in primary spontaneous pneumothorax: a systematic review and meta-analysis.
- Author
-
Walker SP, Bibby AC, Halford P, Stadon L, White P, and Maskell NA
- Subjects
- Humans, Randomized Controlled Trials as Topic, Recurrence, Risk Factors, Sex Factors, Pneumothorax epidemiology
- Abstract
Primary spontaneous pneumothorax (PSP) recurrence rates vary widely in the published literature, with limited data describing the factors that influence recurrence. The aims of this systematic review were to determine an estimation of PSP recurrence rates and describe risk factors for recurrence.A systematic review was conducted of all studies reporting PSP recurrence. Electronic searches were performed to identify English language publications of randomised trials and observational studies. The population was adults with PSP, who underwent conservative management, pleural aspiration or chest drainage. The outcome of interest was recurrence. Articles were screened and data extracted from eligible studies by two reviewers.Of 3607 identified studies, 29 were eligible for inclusion, comprising 13 548 patients. Pooled 1-year and overall recurrence rates were 29.0% (95% CI 20.9-37.0%) and 32.1% (95% CI 27.0-37.2%), respectively. Female sex was associated with increased recurrence (OR 3.03, 95% CI 1.24-7.41), while smoking cessation was associated with a four-fold decrease in risk (OR 0.26, 95% CI 0.10-0.63). I
2 for random effects meta-analysis was 94% (p<0.0001), reflecting high heterogeneity between studies.This systematic review demonstrates a 32% PSP recurrence rate, with greatest risk in the first year. Female sex was associated with higher risk, suggesting possible sex-specific pathophysiology., Competing Interests: Conflict of interest: None declared., (Copyright ©ERS 2018.)- Published
- 2018
- Full Text
- View/download PDF
15. Are intra-pleural bacterial products associated with longer survival in adults with malignant pleural effusions? A systematic review.
- Author
-
Bibby AC, Walker S, and Maskell NA
- Subjects
- Adult, Humans, Pleura microbiology, Publication Bias, Randomized Controlled Trials as Topic, Survival Analysis, Antigens, Bacterial administration & dosage, Pleura physiology, Pleural Effusion, Malignant therapy, Pleurodesis methods
- Abstract
Background: Intra-pleural bacteria are effective pleurodesis agents in malignant pleural effusions. However, their relationship with survival is unclear., Objectives: We undertook a comprehensive, structured evaluation of survival outcomes in adults with malignant pleural effusions treated with intra-pleural bacterial products., Data Sources: Medline, Embase, Cochrane library, Clinical Trials Registers and Open Grey., Study Eligibility Criteria, Participants, and Interventions: Randomised controlled trials and non-randomised comparative studies were included, if the population included adults with malignant pleural effusions. Interventions of interest were any intra-pleural bacterial product, compared with placebo, alternative intra-pleural drug, or no treatment. Survival outcomes were collected., Study Appraisal and Synthesis Methods: Two reviewers independently screened studies for eligibility, assessed papers for risk of bias and extracted data. Narrative synthesis was performed as high heterogeneity between studies precluded meta-analysis., Results: 631 studies were identified, of which 14 were included. All were at high or unclear risk of bias in at least one domain. Six studies reported a survival benefit associated with intra-pleural bacterial products, whilst 8 reported no difference. Non-randomised studies and studies published prior to 2000 were more likely to report survival benefits., Limitations: There was high heterogeneity between studies, which limited the generalisability of findings. Publication bias may have affected the review as five full-text papers were unobtainable, and survival outcomes were missing in a further five., Conclusions: There is a lack of high quality evidence regarding the relationship between intra-pleural bacterial products and survival. Implications of key findings: Well-designed, prospective randomised trials are needed, to determine whether intra-pleural bacterial products can improve survival in pleural malignancy., Prospero Registration Number: CRD42017058067., (Copyright © 2018 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
16. ERS/EACTS statement on the management of malignant pleural effusions.
- Author
-
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, and Maskell NA
- Subjects
- Advisory Committees, Drainage adverse effects, Europe, Humans, Pleural Effusion, Malignant diagnostic imaging, Pleural Effusion, Malignant epidemiology, Pleurodesis adverse effects, Recurrence, Retreatment, Risk Factors, Societies, Medical, Thoracentesis adverse effects, Drainage methods, Palliative Care methods, Pleural Effusion, Malignant therapy, Pleurodesis methods, Thoracentesis methods
- Abstract
Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE management. The European Respiratory Society (ERS) and the European Association for Cardio-Thoracic Surgery (EACTS) established a multidisciplinary collaboration of clinicians with expertise in the management of MPE with the aim of producing a comprehensive review of the scientific literature.Six areas of interest were identified, including the optimum management of symptomatic MPE, management of trapped lung in MPE, management of loculated MPE, prognostic factors in MPE, whether there is a role for oncological therapies prior to intervention for MPE and whether a histological diagnosis is always required in MPE.The literature revealed that talc pleurodesis and indwelling pleural catheters effectively manage the symptoms of MPE. There was limited evidence regarding the management of trapped lung or loculated MPE. The LENT score was identified as a validated tool for predicting survival in MPE, with Brims' prognostic score demonstrating utility in mesothelioma prognostication. There was no evidence to support the use of oncological therapies as an alternative to MPE drainage, and the literature supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning., Competing Interests: Conflict of interest: A.C. Bibby reports grants from National Institute of Health Research (DRF-2016-09-065), outside the submitted work. Conflict of interest: I. Psallidas is a Medical Science Director for AstraZeneca in a different research area than the submitted work. Conflict of interest: P. Licht reports personal fees (speaker's honorarium) from Ethicon, outside the submitted work. Conflict of interest: A. Scherpereel reports personal fees (for advisory board participation) from BMS, MSD, Boehringer Ingelheim and Roche, and has been an investigator in clinical trials (fees paid to institution, CHU de Lille, France) for AstraZeneca, Lilly, BMS, MSD, Boehringer Ingelheim and Roche, outside the submitted work. Conflict of interest: N.M. Rahman reports personal fees for consultancy work from Rocket Medical UK, outside the submitted work. Conflict of interest: N.A. Maskell reports unrestricted research grants from Becton Dickinson and Rocket, outside the submitted work, and is a member of the advisory board for Becton Dickinson., (The article has been co-published with permission in the European Respiratory Journal and the European Journal of Cardio-Thoracic Surgery. All rights reserved in respect of European Respiratory Journal, © European Respiratory Society 2018 and European Journal of Cardio-Thoracic Surgery, © European Association for Cardio-Thoracic Surgery 2018. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.)
- Published
- 2018
- Full Text
- View/download PDF
17. Current treatments and trials in malignant pleural mesothelioma.
- Author
-
Bibby AC and Maskell NA
- Subjects
- Angiogenesis Inhibitors therapeutic use, Clinical Trials as Topic, Humans, Immunotherapy methods, Mesothelioma, Malignant, Molecular Targeted Therapy, Treatment Outcome, Antineoplastic Agents therapeutic use, Lung Neoplasms therapy, Mesothelioma therapy, Pulmonary Surgical Procedures methods, Radiotherapy methods
- Abstract
Objectives: This article aims to review the evidence from recent clinical trials in mesothelioma, and to provide an overview of relevant clinical trials that are currently in progress., Data Source: Ovid MEDLINE, 1946 to present., Study Selection: Clinical trials of therapeutic interventions were considered for inclusion, regardless of phase. Of 258 papers identified in the literature search, 88 were potentially eligible based on abstract screening. Following evaluation of full-text articles, 35 were selected for inclusion in the review., Results: Since the original trial that demonstrated the efficacy of pemetrexed and cisplatin in mesothelioma, multiple trials have been conducted that have further informed management options. Anti-angiogenesis agents such as bevacizumab and nintedanib appear promising as adjuncts to first-line chemotherapy. Meanwhile, immunotherapy, anti-mesothelin agents and molecular targeted therapies are potential areas for development, with ongoing trials promising to deliver interesting results over the next few years. Current evidence does not support surgical intervention; however, investigations are ongoing as to the role of extended pleurectomy/decortication, and surgery in the context of trapped lung. Finally radiotherapy is effective as a palliative measure for pain control, but is not indicated prophylactically to prevent the development of procedure tract metastases., Conclusion: A large amount of high-quality mesothelioma research has been conducted in the past decade. As a result, several new therapies are likely to become available in clinical practice in the near future. With multiple trials ongoing, the horizon for patients with mesothelioma looks brighter than ever before., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
18. Benign pleural schwannoma presenting with a large, blood-stained pleural effusion.
- Author
-
Bibby AC, Daly R, Internullo E, Edey AJ, and Maskell NA
- Subjects
- Adult, Humans, Male, Neurilemmoma diagnostic imaging, Neurilemmoma pathology, Pleural Effusion diagnostic imaging, Pleural Neoplasms diagnostic imaging, Pleural Neoplasms pathology, Positron Emission Tomography Computed Tomography, Neurilemmoma complications, Pleural Effusion etiology, Pleural Neoplasms complications
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2018
- Full Text
- View/download PDF
19. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion.
- Author
-
Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Haris M, Harrison RN, Mustafa RA, Bishop LJ, Ahmed L, West A, Holme J, Evison M, Munavvar M, Sivasothy P, Herre J, Cooper D, Roberts M, Guhan A, Hooper C, Walters J, Saba TS, Chakrabarti B, Gunatilake S, Psallidas I, Walker SP, Bibby AC, Smith S, Stadon LJ, Zahan-Evans NJ, Lee YCG, Harvey JE, Rahman NM, Miller RF, and Maskell NA
- Subjects
- Aged, Ambulatory Care, Catheters, Indwelling, Female, Humans, Male, Middle Aged, Pleural Effusion, Malignant mortality, Pleurodesis adverse effects, Quality of Life, Single-Blind Method, Survival Analysis, Pleural Effusion, Malignant therapy, Pleurodesis methods, Talc administration & dosage
- Abstract
Background: Malignant pleural effusion affects more than 750,000 persons each year across Europe and the United States. Pleurodesis with the administration of talc in hospitalized patients is the most common treatment, but indwelling pleural catheters placed for drainage offer an ambulatory alternative. We examined whether talc administered through an indwelling pleural catheter was more effective at inducing pleurodesis than the use of an indwelling pleural catheter alone., Methods: Over a period of 4 years, we recruited patients with malignant pleural effusion at 18 centers in the United Kingdom. After the insertion of an indwelling pleural catheter, patients underwent drainage regularly on an outpatient basis. If there was no evidence of substantial lung entrapment (nonexpandable lung, in which lung expansion and pleural apposition are not possible because of visceral fibrosis or bronchial obstruction) at 10 days, patients were randomly assigned to receive either 4 g of talc slurry or placebo through the indwelling pleural catheter on an outpatient basis. Talc or placebo was administered on a single-blind basis. Follow-up lasted for 70 days. The primary outcome was successful pleurodesis at day 35 after randomization., Results: The target of 154 patients undergoing randomization was reached after 584 patients were approached. At day 35, a total of 30 of 69 patients (43%) in the talc group had successful pleurodesis, as compared with 16 of 70 (23%) in the placebo group (hazard ratio, 2.20; 95% confidence interval, 1.23 to 3.92; P=0.008). No significant between-group differences in effusion size and complexity, number of inpatient days, mortality, or number of adverse events were identified. No significant excess of blockages of the indwelling pleural catheter was noted in the talc group., Conclusions: Among patients without substantial lung entrapment, the outpatient administration of talc through an indwelling pleural catheter for the treatment of malignant pleural effusion resulted in a significantly higher chance of pleurodesis at 35 days than an indwelling catheter alone, with no deleterious effects. (Funded by Becton Dickinson; EudraCT number, 2012-000599-40 .).
- Published
- 2018
- Full Text
- View/download PDF
20. Commentary: considerations for using the 'Trials within Cohorts' design in a clinical trial of an investigational medicinal product.
- Author
-
Bibby AC, Torgerson DJ, Leach S, Lewis-White H, and Maskell NA
- Subjects
- Ethics Committees, Humans, Informed Consent, Patient Selection, Pragmatic Clinical Trials as Topic ethics, Pragmatic Clinical Trials as Topic standards, Randomized Controlled Trials as Topic ethics, Randomized Controlled Trials as Topic standards, Research Support as Topic, Workflow, Pragmatic Clinical Trials as Topic methods, Randomized Controlled Trials as Topic methods, Research Design standards
- Abstract
Background: The 'trials within cohorts' (TwiC) design is a pragmatic approach to randomised trials in which trial participants are randomly selected from an existing cohort. The design has multiple potential benefits, including the option of conducting multiple trials within the same cohort., Main Text: To date, the TwiC design methodology been used in numerous clinical settings but has never been applied to a clinical trial of an investigational medicinal product (CTIMP). We have recently secured the necessary approvals to undertake the first CTIMP using the TwiC design. In this paper, we describe some of the considerations and modifications required to ensure such a trial is compliant with Good Clinical Practice and international clinical trials regulations. We advocate using a two-stage consent process and using the consent stages to explicitly differentiate between trial participants and cohort participants who are providing control data. This distinction ensured compliance but had consequences with respect to costings, recruitment and the trial assessment schedule., Conclusion: We have demonstrated that it is possible to secure ethical and regulatory approval for a CTIMP TwiC. By including certain considerations at the trial design stage, we believe this pragmatic and efficient methodology could be utilised in other CTIMPs in future.
- Published
- 2018
- Full Text
- View/download PDF
21. Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study.
- Author
-
Bibby AC, De Fonseka D, Morley AJ, Keenan E, Addeo A, Smith S, Edey AJ, and Maskell NA
- Subjects
- Aged, Drug Therapy, Combination methods, Female, Humans, Male, Mesothelioma psychology, Middle Aged, Prospective Studies, Retrospective Studies, Survival Analysis, United Kingdom, Choice Behavior, Drug Therapy, Combination psychology, Mesothelioma therapy, Symptom Flare Up
- Abstract
Background: Mesothelioma is an aggressive thoracic tumour with a poor prognosis. The only treatment that extends survival is chemotherapy. However, in the UK, up to 50% of patients who are suitable for chemotherapy choose not to receive it, opting for active symptom control instead. The aim of this prospective, single-centre observational study was to describe the characteristics of patients who chose active symptom control over chemotherapy and explore their reasons for doing so., Methods: Two hundred consecutive patients with mesothelioma from one UK centre were included. Eligibility for chemotherapy and choice of first-line treatment were recorded prospectively. Patient characteristics and outcomes were compared using descriptive statistics, regression analysis and survival analysis. Reasons for choosing active symptom control over chemotherapy were extracted, retrospectively., Results: People who chose active symptom control were older, more likely to be female and had worse performance statuses than patients who received front-line chemotherapy. Concern over side effects, the modest survival benefit and previous adverse experiences with chemotherapy were reported as reasons for the decision. Median survival was 13.9 months in the chemotherapy group compared with 6.7 months in the active symptom control group., Conclusions: This is the first study to describe the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy, in the front-line setting. Important differences were seen between this group and patients who received chemotherapy, although confounding is likely to have affected some outcomes. Future research could use qualitative methods to explore patients' reasons for choosing active symptom control, and to further elucidate the decision-making process.
- Published
- 2017
- Full Text
- View/download PDF
22. Current best practice in the evaluation and management of malignant pleural effusions.
- Author
-
Walker S, Bibby AC, and Maskell NA
- Subjects
- Humans, Phenotype, Pleural Effusion, Malignant mortality, Pleural Effusion, Malignant physiopathology, Prognosis, Randomized Controlled Trials as Topic, Research Design, Pleural Effusion, Malignant therapy, Precision Medicine methods
- Abstract
Malignant pleural effusions (MPEs) are an important cause of cancer-related mortality and morbidity. It is a heterogeneous group of conditions, which leads to debilitating symptoms and confers a poor prognosis. Recent well-designed randomized trials have provided a broader evidence base for an expanding range of treatment options. Together, with new prognostic scoring systems and a greater understanding of how different patient phenotypes respond to treatment, this allows greater personalization of management. This article will discuss the current evidence on evaluation and management of MPEs.
- Published
- 2017
- Full Text
- View/download PDF
23. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
- Author
-
Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, and Psallidas I
- Subjects
- Humans, Lung Neoplasms pathology, Mesothelioma pathology, Mesothelioma, Malignant, Pleural Neoplasms pathology, Predictive Value of Tests, Treatment Outcome, Lung Neoplasms diagnosis, Lung Neoplasms therapy, Mesothelioma diagnosis, Mesothelioma therapy, Pleural Neoplasms diagnosis, Pleural Neoplasms therapy
- Abstract
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to peak in the next few years.This article summarises the epidemiology and pathogenesis of malignant pleural mesothelioma, before describing some key factors in the patient experience and outlining common symptoms. Diagnostic approaches are reviewed, including imaging techniques and the role of various biomarkers. Treatment options are summarised, including the importance of palliative care and methods of controlling pleural effusions. The evidence for chemotherapy, radiotherapy and surgery is reviewed, both in the palliative setting and in the context of trimodality treatment. An algorithm for managing malignant pleural effusion in malignant pleural mesothelioma patients is presented. Finally new treatment developments and novel therapeutic approaches are summarised., (Copyright ©ERS 2016.)
- Published
- 2016
- Full Text
- View/download PDF
24. What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK.
- Author
-
Bibby AC, Williams K, Smith S, Bhatt N, and Maskell NA
- Subjects
- Aged, Aged, 80 and over, Diagnosis, Differential, England, Female, Humans, Male, Middle Aged, Specialization, Mesothelioma diagnosis, Patient Care Team, Professional Role, Referral and Consultation, Tertiary Care Centers
- Abstract
Background: Multidisciplinary team meetings are standard care for cancer in the UK and Europe. Professional bodies recommend that mesothelioma cases should be discussed at specialist multidisciplinary team meetings. However, no evidence exists exploring the role of the specialist mesothelioma multidisciplinary team meeting., Objectives: To evaluate the clinical activity of 1 specialist mesothelioma multidisciplinary team meeting and to determine how often a definitive diagnosis was made, whether the core requirements of the meeting were met and whether there was any associated benefit or detriment., Design and Setting: A service evaluation using routinely collected data from 1 specialist mesothelioma multidisciplinary team meeting in a tertiary referral hospital in the South-West of England., Participants: All cases discussed between 1/1/2014 and 31/12/2015., Outcome Measures: The primary outcome measure was whether a definitive diagnosis was made. Secondary outcomes included whether treatment advice was offered, information on clinical trials provided or further investigations suggested. Additional benefits of the multidisciplinary team meeting and time taken from referral to outcome were also collected., Results: A definitive diagnosis was reached in 171 of 210 cases discussed (81%). Mesothelioma was diagnosed in 153/210 (73%). Treatment advice was provided for 127 of 171 diagnostic cases (74%) and further investigations suggested for all 35 non-diagnostic cases. 86/210 cases (41%) were invited to participate in a trial, of whom 43/86 (50%) subsequently enrolled. Additional benefits included the avoidance of postmortem examination if the coroner was satisfied with the multidisciplinary team decision. The overall process from referral to outcome dispatch was <2 weeks in 75% of cases., Conclusions: This specialist mesothelioma multidisciplinary team meeting was effective at making diagnoses and providing recommendations for further investigations or treatment. The core requirements of a specialist mesothelioma multidisciplinary team meeting were met. The process was timely, with most outcomes returned within 2 weeks of referral., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Published
- 2016
- Full Text
- View/download PDF
25. Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies.
- Author
-
Bibby AC and Maskell NA
- Subjects
- Humans, Image-Guided Biopsy, Thoracoscopy, Biopsy methods, Pleura pathology, Pleural Effusion etiology
- Abstract
Purpose of Review: Pleural biopsies are often necessary if a pleural effusion remains undiagnosed after radiological imaging and pleural fluid analysis. There are many methods of obtaining pleural biopsies, including blind or image-guided procedures, closed-bevel or cutting-edge needles, and percutaneous or thoracoscopic approaches. This article will review recent research relating to these methods, aiming to provide an overview of the strengths and limitations of each technique., Recent Findings: Historically pleural biopsies were undertaken using a blind closed 'Abrams' needle method. However, low diagnostic yields and high complication rates are seen with this technique compared with newer methods. Recent research compares image-guided, cutting-needle approaches to traditional Abrams biopsies, and evaluates the role of medical thoracoscopy in comparison to other techniques., Summary: Thoracoscopic biopsies are the gold standard for investigating pleural disease. However, this service is not universally available and may be unsuitable for some patients. Image-guided cutting-needle biopsies under computed tomography or ultrasound guidance have high diagnostic rates and are useful in a wide patient population. The main role of Abrams biopsies is in the diagnosis of tuberculous pleuritis in resource-poor settings.
- Published
- 2016
- Full Text
- View/download PDF
26. Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection: A Retrospective Case Review From Six UK Centers.
- Author
-
Bibby AC, Clive AO, Slade GC, Morley AJ, Fallon J, Psallidas I, Pepperell JCT, Slade MG, Stanton AE, Rahman NM, and Maskell NA
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Pleural Effusion, Malignant pathology, Pleural Effusion, Malignant therapy, Retrospective Studies, Survival Rate, United Kingdom, Catheter-Related Infections mortality, Catheterization adverse effects, Catheters, Indwelling adverse effects, Pleural Effusion, Malignant mortality, Pleurisy mortality
- Abstract
Objective: Malignant pleural effusion (MPE) incidence is increasing, and prognosis remains poor. Indwelling pleural catheters (IPCs) relieve symptoms but increase the risk of pleural infection. We reviewed cases of pleural infection in patients with IPCs for MPE from six UK centers between January 1, 2005, and January 31, 2014., Methods: Survival in patients with pleural infection was compared with 788 patients with MPE (known as the LENT [pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, serum neutrophil to lymphocyte ratio, and tumor type] cohort) and with national statistics., Results: Of 672 IPCs inserted, 25 (3.7%) became infected. Most patients (20 of 25) had mesothelioma or lung cancer. Median survival in the pleural infection cohort appeared longer than in the LENT cohort, although this result did not achieve significance (386 days vs 132 days; hazard ratio, 0.67; P = .07). Median survival with mesothelioma and pleural infection was twice as long as national estimates for mesothelioma survival (753 days vs < 365 days) and double the median survival of patients with mesothelioma in the LENT cohort (339 days; 95% CI, nonoverlapping). Survival with lung and breast cancer did not differ significantly between the groups. Sixty-one percent of patients experienced early infection. There was no survival difference between patients with early and late infection (P = .6)., Conclusions: This small series of patients with IPCs for MPE suggests pleural infection may be associated with longer survival, particularly in patients with mesothelioma. Results did not achieve significance, and a larger study is needed to explore this relationship further and investigate whether the local immune response, triggered by infection, is able to modulate mesothelioma progression.
- Published
- 2015
- Full Text
- View/download PDF
27. Medical and oncological management of malignant mesothelioma.
- Author
-
Bibby AC, Gibbs L, and Braybrooke JP
- Subjects
- Catheters, Indwelling, Chest Tubes, Folic Acid Antagonists therapeutic use, Humans, Mesothelioma, Malignant, Pleural Effusion, Malignant therapy, Antineoplastic Agents therapeutic use, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Mesothelioma drug therapy, Mesothelioma radiotherapy
- Abstract
Mesothelioma is an aggressive cancer, for which no curative oncological treatment currently exists. This article outlines the options for managing malignant pleural effusions, describes the developments in chemotherapy over the past 10 years and summarizes the evidence for prophylactic and palliative radiotherapy.
- Published
- 2015
- Full Text
- View/download PDF
28. Nutritional management in chyle leaks and chylous effusions.
- Author
-
Bibby AC and Maskell NA
- Subjects
- Humans, Chyle, Enteral Nutrition, Parenteral Nutrition
- Abstract
Chyle leaks occur when there is interruption to the lymphatic ducts that transport chyle around the body. The loss of this protein-rich, calorie-rich fluid can cause serious complications including dehydration, malnutrition and immunosuppression. Treatment of chyle leaks depends on the underlying cause, which may be surgical, secondary to malignant invasion or the result of a medical condition. Nutritional support is vital and leads to spontaneous leak closure in many cases. Nutritional management options include total bowel rest with parenteral nutrition, enteral feeding with specialized formula, or oral diet with supplementation. At present there is no consensus regarding which approach is superior. In reality, most patients with chyle leaks are managed with a combination or oral and enteral feeding, but further work is needed to clarify the optimum management strategy.
- Published
- 2014
- Full Text
- View/download PDF
29. Pleural procedures: intercostal chest drains and indwelling pleural catheters.
- Author
-
Bibby AC and Maskell NA
- Subjects
- Chest Tubes adverse effects, Chest Tubes standards, Drainage adverse effects, Drainage instrumentation, Humans, Pleural Effusion complications, Safety, Catheters, Indwelling adverse effects, Catheters, Indwelling standards, Drainage methods, Pleural Effusion therapy
- Abstract
Drainage of pleural effusions is often necessary to keep patients symptom free. This article describes two methods of removing pleural fluid and outlines the insertion procedure. Indications, potential complications and post-procedure management are also discussed.
- Published
- 2011
- Full Text
- View/download PDF
30. Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura?
- Author
-
Bibby AC, Farrell A, Cummins M, and Erlewyn-Lajeunesse M
- Subjects
- Child, Chronic Disease, Female, Humans, Infant, Male, Platelet Count, Measles-Mumps-Rubella Vaccine adverse effects, Purpura, Thrombocytopenic, Idiopathic complications
- Published
- 2008
- Full Text
- View/download PDF
31. The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta.
- Author
-
Bibby AC and Litchfield DW
- Subjects
- Amino Acid Motifs, Amino Acid Sequence, Animals, Casein Kinase II chemistry, Casein Kinase II genetics, Cell Compartmentation, Cell Cycle, Eukaryotic Cells enzymology, Humans, Mice, Models, Molecular, Molecular Sequence Data, Phosphorylation, Protein Binding, Protein Conformation, Protein Interaction Mapping, Protein Processing, Post-Translational, Protein Serine-Threonine Kinases metabolism, Protein Subunits, Saccharomyces cerevisiae Proteins physiology, Sequence Alignment, Sequence Homology, Amino Acid, Structure-Activity Relationship, Casein Kinase II physiology
- Abstract
Protein kinase CK2 (formerly casein kinase II), an enzyme that participates in a wide variety of cellular processes, has traditionally been classified as a stable tetrameric complex consisting of two catalytic CK2alpha or CK2alpha' subunits and two regulatory CK2beta subunits. While consideration of CK2 as a tetrameric complex remains relevant, significant evidence has emerged to challenge the view that its individual subunits exist exclusively within these complexes. This review will summarize biochemical and genetic evidence indicating that the regulatory CK2beta subunit exists and performs functions independently of CK2 tetramers. For example, unbalanced expression of catalytic and regulatory CK2 subunits has been observed in a variety of tissues and tumors. Furthermore, localization studies including live cell imaging have demonstrated that while the catalytic and regulatory subunits of CK2 exhibit extensive co-localization, independent mobility of the individual CK2 subunits can also be observed within cells. Identification of proteins that interact with CK2beta in the absence of catalytic CK2 subunits reinforces the notion that CK2beta has functions distinct from CK2 and begins to offer insights into these CK2-independent functions. In this respect, the discovery that CK2beta can interact with and modulate the activity of a number of other serine/threonine protein kinases including A-Raf, c-Mos and Chk1 is particularly striking. This review will discuss the interactions between CK2beta and these protein kinases with special emphasis on the properties of CK2beta that mediate these interactions and on the implications of these interactions in yielding new prospects for elucidation of the cellular functions of CK2beta.
- Published
- 2005
- Full Text
- View/download PDF
32. Inhibition of protein kinase C catalytic activity by additional regions within the human protein kinase Calpha-regulatory domain lying outside of the pseudosubstrate sequence.
- Author
-
Kirwan AF, Bibby AC, Mvilongo T, Riedel H, Burke T, Millis SZ, and Parissenti AM
- Subjects
- Animals, Calcium metabolism, Catalytic Domain, Cattle, Cell Division drug effects, DNA Primers chemistry, Enzyme Activation, Galactose pharmacology, Glutathione Transferase metabolism, Humans, Immunoblotting, Models, Molecular, Mutagenesis, Site-Directed, Mutation, Peptide Fragments metabolism, Phorbol Esters pharmacology, Phosphatidylserines metabolism, Polymerase Chain Reaction, Protamines metabolism, Protein Kinase C-alpha, Protein Structure, Tertiary, Rats, Recombinant Fusion Proteins biosynthesis, Recombinant Fusion Proteins chemistry, Recombinant Fusion Proteins metabolism, Saccharomyces cerevisiae enzymology, Saccharomyces cerevisiae metabolism, Sequence Deletion, Substrate Specificity, Brain enzymology, Protein Kinase C antagonists & inhibitors
- Abstract
The N-terminal pseudosubstrate site within the protein kinase Calpha (PKCalpha)-regulatory domain has long been regarded as the major determinant for autoinhibition of catalytic domain activity. Previously, we observed that the PKC-inhibitory capacity of the human PKCalpha-regulatory domain was only reduced partially on removal of the pseudosubstrate sequence [Parissenti, Kirwan, Kim, Colantonio and Schimmer (1998) J. Biol. Chem. 273, 8940-8945]. This finding suggested that one or more additional region(s) contributes to the inhibition of catalytic domain activity. To assess this hypothesis, we first examined the PKC-inhibitory capacity of a smaller fragment of the PKCalpha-regulatory domain consisting of the C1a, C1b and V2 regions [GST-Ralpha(39-177): this protein contained the full regulatory domain of human PKCalpha fused to glutathione S-transferase (GST), but lacked amino acids 1-38 (including the pseudosubstrate sequence) and amino acids 178-270 (including the C2 region)]. GST-Ralpha(39-177) significantly inhibited PKC in a phorbol-independent manner and could not bind the peptide substrate used in our assays. These results suggested that a region within C1/V2 directly inhibits catalytic domain activity. Providing further in vivo support for this hypothesis, we found that expression of N-terminally truncated pseudosubstrate-less bovine PKCalpha holoenzymes in yeast was capable of inhibiting cell growth in a phorbol-dependent manner. This suggested that additional autoinhibitory force(s) remained within the truncated holoenzymes that could be relieved by phorbol ester. Using tandem PCR-mediated mutagenesis, we observed that mutation of amino acids 33-86 within GST-Ralpha(39-177) dramatically reduced its PKC-inhibitory capacity when protamine was used as substrate. Mutagenesis of a broad range of sequences within C2 (amino acids 159-242) also significantly reduced PKC-inhibitory capacity. Taken together, these observations support strongly the existence of multiple regions within the PKCalpha-regulatory domain that play a direct role in the inhibition of catalytic domain activity.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.